TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9173270

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Accelerated thrombolytic therapy with recombinant tissue plasminogen activator (t-PA)
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty with heparin
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty with hirudin
Number of subjects: 1138
Study: 7513879

Group type: EXPERIMENTAL
Intervention: Mode A
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mode B
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mode C
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall ATP
Number of subjects: 65
Study: 3588512

Group type: EXPERIMENTAL
Intervention: Disopyramide administered as a bolus injection of 150 mg over 5 min.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Disopyramide administered as a bolus injection of 150 mg over 20 min.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Disopyramide administered over 5 min.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Disopyramide administered over 20 min.
Number of subjects: 7
Study: 29926307

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy with modified D2 lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 0
Study: 28072761

Group type: EXPERIMENTAL
Intervention: Urgent chest X-ray
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 255
Study: 25851062

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (dosage and duration not specified)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard therapy (intravenous unfractionated heparin followed by warfarin)
Number of subjects: 97
Study: 23086589

Group type: EXPERIMENTAL
Intervention: Partners in Care intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 82
Study: 21094670

Group type: EXPERIMENTAL
Intervention: Monochromatic blue light exposure for 60 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monochromatic red light exposure for 60 min
Number of subjects: 20
Study: 18501867

Group type: EXPERIMENTAL
Intervention: Culturally effective health care (CEHC) curriculum
Number of subjects: 91
Study: 16569468

Group type: EXPERIMENTAL
Intervention: Patient-self assessment/provider reminder tool (A/R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise reminder (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Exercise reminder)
Number of subjects: 0
Study: 12660530

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/RTV) 800 mg/100 mg q12h
Number of subjects: 323

Group type: COMPARATOR
Intervention: Indinavir (IDV) 800 mg q8h
Number of subjects: 323
Study: 11908356

Group type: EXPERIMENTAL
Intervention: New formulation dentifrice containing 5.0% potassium nitrate and 0.454% stannous fluoride in a silica base
Number of subjects: 66

Group type: COMPARATOR
Intervention: Commercially available nondesensitizing control dentifrice (Colgate Winterfresh Gel)
Number of subjects: 66
Study: 8704665

Group type: EXPERIMENTAL
Intervention: Home health services (skilled nursing services)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No home health services
Number of subjects: 0
Study: 7877829

Group type: EXPERIMENTAL
Intervention: Fat Mobilisation System (FMS) - bandaging with elasticated bandages soaked in active solution able to lower body temperature by 2-3 degrees C
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Fat Mobilisation System (FMS)
Number of subjects: 109
Study: 3356931

Group type: EXPERIMENTAL
Intervention: Simple occlusal adjustment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mock adjustment (placebo)
Number of subjects: 22
Study: 30788810

Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29655779

Group type: EXPERIMENTAL
Intervention: VERSAFIBE™ 2470 resistant starch muffin top (11.6 g TDF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control muffin top (0.9 g TDF)
Number of subjects: 28
Study: 28932087

Group type: EXPERIMENTAL
Intervention: 13C‐urea breath test (UBT) with new test meal after 29 days of esomeprazole 40 mg
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 13C‐urea breath test (UBT) with new test meal
Number of subjects: 114
Study: 24576686

Group type: EXPERIMENTAL
Intervention: Testosterone administration (within normal physiologic range)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gonadotropin releasing hormone antagonist
Number of subjects: 16
Study: 22133572

Group type: COMPARATOR
Intervention: 5‐fluorouracil/folinic acid (FUFA)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil/folinic acid and irinotecan (FOLFIRI)
Number of subjects: 168
Study: 21040559

Group type: EXPERIMENTAL
Intervention: Multidisciplinary stress treatment programme
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (one-hour consultation)
Number of subjects: 63
Study: 17414590

Group type: EXPERIMENTAL
Intervention: metformin + low-dose glimepiride + ADA diet + physical activity
Number of subjects: 70

Group type: COMPARATOR
Intervention: metformin + ADA diet + physical activity
Number of subjects: 70

Group type: COMPARATOR
Intervention: ADA diet + physical activity (no drugs)
Number of subjects: 70
Study: 15723868

Group type: EXPERIMENTAL
Intervention: Bi-annual professional application of APF foam
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 11902986

Group type: EXPERIMENTAL
Intervention: terbinafine (250 mg/d for 12 or 16 weeks)
Number of subjects: 151

Group type: COMPARATOR
Intervention: itraconazole (400 mg/d for 1 week in every 4 for 12 or 16 weeks)
Number of subjects: 151

Group type: COMPARATOR
Intervention: itraconazole
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: terbinafine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: subsequent terbinafine treatment
Number of subjects: 151
Study: 9835306

Group type: EXPERIMENTAL
Intervention: AUDIT consumption questions 1 to 3
Number of subjects: 441
Study: 8291967

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) therapy for shoulder muscles (supraspinatus and posterior deltoid), up to 6 hours a day for 6 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 26
Study: 2971913

Group type: EXPERIMENTAL
Intervention: Experimentally induced stressor and personally relevant stressors during the premenstrual phase for group 1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Experimentally induced stressor and personally relevant stressors during the premenstrual phase for group 2
Number of subjects: 39
Study: 30685298

Group type: EXPERIMENTAL
Intervention: Whole grain/bran rye products (RP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Refined wheat products with added cellulose (WP)
Number of subjects: 17
Study: 29429459

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii powder combined with azithromycin sequential therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine treatment combined with azithromycin sequential therapy
Number of subjects: 88
Study: 27813248

Group type: EXPERIMENTAL
Intervention: Low-polyphenol diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-ET diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 24
Study: 26164587

Group type: EXPERIMENTAL
Intervention: 100% O(2) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham O(2) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham O(2) after O(2) preconditioning
Number of subjects: 0
Study: 22985547

Group type: EXPERIMENTAL
Intervention: Mood management module
Number of subjects: 7763

Group type: EXPERIMENTAL
Intervention: Cigarette counter
Number of subjects: 7763

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy guide
Number of subjects: 7763

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 7763
Study: 21575939

Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol inserted into the posterior vaginal fornix 3 hours before OH
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vaginal examination without misoprostol administration (control)
Number of subjects: 150
Study: 17506119

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (600 microg Cr(+3)) with biotin (2 mg)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 447
Study: 17060120

Group type: EXPERIMENTAL
Intervention: Gluten-free diet supplemented with wheat-free oat products (GFD-oats)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard gluten-free diet (GFD-std)
Number of subjects: 116
Study: 14631219

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laparoscopic rebanding
Number of subjects: 62
Study: 11149635

Group type: EXPERIMENTAL
Intervention: Cold blood ante/retro cardioplegia
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cold crystalloid ante/retro cardioplegia
Number of subjects: 122
Study: 9186096

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.5 mg/ml for 3 1/2 minutes)
Number of subjects: 85

Group type: COMPARATOR
Intervention: 5-fluorouracil (50 mg/ml for 5 minutes)
Number of subjects: 85
Study: 1357551

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (500 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (500 micrograms) after 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3903157

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31182355

Group type: EXPERIMENTAL
Intervention: Simultaneous IUI
Number of subjects: 374

Group type: COMPARATOR
Intervention: Regular IUI
Number of subjects: 374
Study: 30409305

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 250
Study: 25685862

Group type: EXPERIMENTAL
Intervention: Contextual cues during retroactive interference paradigm
Number of subjects: 134

Group type: COMPARATOR
Intervention: No contextual cues during retroactive interference paradigm
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Contextual cues for older adults with high cognitive functioning (Montreal Cognitive Assessment score ≥26)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Contextual cues for older adults with low cognitive functioning (Montreal Cognitive Assessment score <26)
Number of subjects: 134
Study: 23666269

Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control care
Number of subjects: 179
Study: 21947440

Group type: EXPERIMENTAL
Intervention: Partner-assisted emotional disclosure
Number of subjects: 130

Group type: COMPARATOR
Intervention: Education/support control
Number of subjects: 130
Study: 20487038

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155-195 U)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1384
Study: 17989308

Group type: EXPERIMENTAL
Intervention: Insulin aspart CSII
Number of subjects: 298

Group type: COMPARATOR
Intervention: Insulin lispro CSII
Number of subjects: 298
Study: 15667599

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg) inhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of caffeine
Number of subjects: 10
Study: 11980359

Group type: EXPERIMENTAL
Intervention: Artificial neural networks (ANN)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional methods (including unweighted application of criteria, regression coefficients, regression tree analysis)
Number of subjects: 99
Study: 10613642

Group type: EXPERIMENTAL
Intervention: Natural streptokinase (nSK) 1.5 million units, one-hour intravenous infusion
Number of subjects: 224

Group type: COMPARATOR
Intervention: Recombinant streptokinase (rSK) 1.5 million units, one-hour intravenous infusion
Number of subjects: 224
Study: 7844604

Group type: EXPERIMENTAL
Intervention: Continuous infusion fluorouracil (5FU) 200 mg/m2/d via a Hick‐man line for 6 months with epirubicin 50 mg/m2 IV and cisplatin 60 mg/m2 IV every 3 weeks for eight courses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional chemotherapy (control group)
Number of subjects: 50
Study: 1742815

Group type: EXPERIMENTAL
Intervention: 0.25 mg.kg‐1 ketamine iv
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 ketamine iv
Number of subjects: 20
Study: 6285279

Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31353126

Group type: EXPERIMENTAL
Intervention: Vocal Facilitating Techniques (VFTs); 10 individual sessions, twice a week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual Circumlaryngeal Therapy (MCT); 10 individual sessions, twice a week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: VFTs
Number of subjects: 16
Study: 30791513

Group type: EXPERIMENTAL
Intervention: Chemical Cluster Environmental Protection Patrolling (CCEPP) game
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed route strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purely randomized route strategy
Number of subjects: 0
Study: 28796913

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g foam
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g gel
Number of subjects: 213

Group type: COMPARATOR
Intervention: Cal/BD foam and gel vs. latest topical treatment (LTT)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cal/BD gel
Number of subjects: 213
Study: 25731215

Group type: EXPERIMENTAL
Intervention: Insulin needle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard needle
Number of subjects: 50
Study: 23844488

Group type: EXPERIMENTAL
Intervention: Percutaneous poking K-wire fixation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Operative reduction (plate group)
Number of subjects: 135
Study: 21044630

Group type: EXPERIMENTAL
Intervention: Radioembolization
Number of subjects: 245

Group type: COMPARATOR
Intervention: Chemoembolization
Number of subjects: 245
Study: 19028932

Group type: EXPERIMENTAL
Intervention: Oleic acid supplements
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16772625

Group type: EXPERIMENTAL
Intervention: Automated load-distributing band (LDB) chest compression device
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 1071
Study: 14759453

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (heparin plus nafamostat, 0.2 mg/kg bolus followed by 2.0 mg/kg/h during cardiopulmonary bypass)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aprotinin (heparin plus aprotinin, 2.0 x 10(4) KIU/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nafamostat mesilate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aprotinin and Nafamostat
Number of subjects: 18
Study: 11279651

Group type: EXPERIMENTAL
Intervention: Nadroparin (low molecular weight heparin)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 279
Study: 9642307

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 40
Study: 8489752

Group type: EXPERIMENTAL
Intervention: Levonorgestrel releasing IUD (LNg IUD)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Copper IUD and controls using no contraception
Number of subjects: 581
Study: 3549083

Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclophosphamide, dipyridamole, and warfarin)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among patients with IgA nephritis (n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no treatment) among patients with IgA nephritis (n = 21)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among matched pairs (n = 23)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no treatment) among matched pairs (n = 23)
Number of subjects: 52
Study: 30945105

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (30 µg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 29665405

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Class I indication for CRT
Number of subjects: 930
Study: 27420318

Group type: EXPERIMENTAL
Intervention: 7 muscle groups PMR
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 16 muscle groups PMR
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 23632352

Group type: EXPERIMENTAL
Intervention: BIO-THREE probiotics
Number of subjects: 159
Study: 22699827

Group type: EXPERIMENTAL
Intervention: Lokomat robotic-assisted training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Overground therapy
Number of subjects: 80
Study: 20846058

Group type: EXPERIMENTAL
Intervention: End-to-end approximation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overlap technique
Number of subjects: 128
Study: 17586139

Group type: EXPERIMENTAL
Intervention: 50 mg of mifepristone once every 14 days for six cycles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15680804

Group type: EXPERIMENTAL
Intervention: Early low-dose steroid therapy (methylprednisolone, 2 mg/kg loading dose followed by 2 mg/kg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study: 12075915

Group type: EXPERIMENTAL
Intervention: Expressive disclosure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-disclosure
Number of subjects: 30
Study: 10605950

Group type: EXPERIMENTAL
Intervention: Low-dose wine group
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose wine group
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study: 7785460

Group type: EXPERIMENTAL
Intervention: UroPhos-K
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2228846

Group type: EXPERIMENTAL
Intervention: Selective decontamination (SDD) with initial systemic cefotaxime (500 mg tid for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group A (antibiotics that disturb colonization resistance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group B (antibiotics not affecting colonization resistance)
Number of subjects: 0
Study: 356244

Group type: EXPERIMENTAL
Intervention: Voltaren (diclofenac sodium) 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31662998

Group type: EXPERIMENTAL
Intervention: Piezosurgery (G2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Drill (G1)
Number of subjects: 65
Study: 27856955

Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 155
Study: 25387477

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg every 4 weeks
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg after dose adjustment
Number of subjects: 356

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 356
Study: 23291315

Group type: EXPERIMENTAL
Intervention: Immediate and uninterrupted skin-to-skin contact at birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rooming-in during postpartum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separation and swaddling at birth
Number of subjects: 0
Study: 21510319

Group type: EXPERIMENTAL
Intervention: 50mg itopride following a test meal (200 kcal per 200mL, containing 100mg 13C acetate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 8
Study: 19698172

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AS&AQ)
Number of subjects: 11700

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 11700

Group type: COMPARATOR
Intervention: Artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Number of subjects: 11700

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 11700
Study: 16076944

Group type: EXPERIMENTAL
Intervention: Physiological recombinant methionyl human leptin
Number of subjects: 20
Study: 12233104

Group type: EXPERIMENTAL
Intervention: Warfarin treatment in group A (sick sinus syndrome with pacemaker)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Warfarin treatment in group B (atrial fibrillation without pacemaker)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Warfarin dosage in group A
Number of subjects: 641

Group type: COMPARATOR
Intervention: Warfarin dosage in group B
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: PT-INR and TT measurements
Number of subjects: 641
Study: 10404735

Group type: EXPERIMENTAL
Intervention: Normotensives
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hypertensives
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 51
Study: 7590502

Group type: EXPERIMENTAL
Intervention: 3 g fish oil
Number of subjects: 32

Group type: COMPARATOR
Intervention: 3 g corn oil (placebo)
Number of subjects: 32
Study: 2138595

Group type: EXPERIMENTAL
Intervention: naloxone 0.4 mg (i.m.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: naloxone 4 mg (i.v.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: naloxone (both doses)
Number of subjects: 15
Study: 6766833

Group type: EXPERIMENTAL
Intervention: Phenobarbital 60 mg orally
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Valproic acid 250 mg orally twice daily for 14 days + Phenobarbital 60 mg orally on day 4
Number of subjects: 6
Study: 31332998

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Omega-3 fatty acids for 3 months
Number of subjects: 48
Study: 27233583

Group type: EXPERIMENTAL
Intervention: Standardized meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 0